Delving into the Latest Updates on Allogenic Adipose MSC-Exos(Cellular Biomedicine) with Synapse

Overview

Basic Info

Drug Type

Exosomes

Synonyms

MSCsExos (Cellular Biomedicine Group)

Target-

Mechanism-

Therapeutic Areas

Nervous System DiseasesRespiratory DiseasesInfectious Diseases

Active Indication-

Inactive Indication

Alzheimer DiseaseCOVID-19Respiratory Distress Syndrome, Acute+ [1]

Originator Organization

AbelZeta Pharma, Inc.

Active Organization-

Inactive Organization

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

AbelZeta Pharma, Inc.

Shanghai Cellular Biopharmaceutical Group Ltd.

Drug Highest PhasePendingPhase 1/2

First Approval Date-

Regulation-

Login to view timeline

Exosomes are naturally occurring nanosized vesicles and comprised of natural lipid bilayers with the abundance of adhesive proteins that readily interact with cellular membranes. These vesicles have a content that includes cytokines and growth factors, signaling lipids, mRNAs, and regulatory miRNAs. Exosomes are involved in cell-to-cell communication, cell signaling, and altering cell or tissue metabolism at short or long distances in the body, and can influence tissue responses to injury, infection, and disease.
Experimental studies have demonstrated that mesenchymal stem cells (MSCs) or their exosomes (MSCs-Exo) significantly reduced lung inflammation and pathological impairment resulting from different types of lung injury. In addition, macrophage phagocytosis, bacterial killing and outcome were improved. It is highly likely that MSCs-Exo have the similar therapeutic effect on inoculation pneumonia as MSCs themselves.
This clinical study will be performed to evaluate the safety and tolerance of aerosol inhalation of the exosomes derived from allogenic adipose mesenchymal stem cells (MSCs-Exo) in healthy volunteers.

Start Date12 Mar 2020

Sponsor / Collaborator

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

[+1]

100 Clinical Results associated with Allogenic Adipose MSC-Exos(Cellular Biomedicine)

Login to view more data

100 Translational Medicine associated with Allogenic Adipose MSC-Exos(Cellular Biomedicine)

Login to view more data

100 Patents (Medical) associated with Allogenic Adipose MSC-Exos(Cellular Biomedicine)

Login to view more data

29

Literatures (Medical) associated with Allogenic Adipose MSC-Exos(Cellular Biomedicine)

01 Mar 2025·PHARMACOLOGICAL RESEARCH

Hydrogels empowered mesenchymal stem cells and the derived exosomes for regenerative medicine in age-related musculoskeletal diseases

Review

Author: Yang, Lina ; Chen, Yiman ; Xia, Jiangli ; Yang, Liqun ; Liu, Lixin ; Fan, Yibo ; Cui, Longwei ; Chen, Siwen ; Song, Yantao

As the population ages, musculoskeletal diseases (MSK) have emerged as a significant burden for individuals, healthcare systems, and social care systems. Recently, regenerative medicine has exhibited vast potential in age-related MSK, with mesenchymal stromal cells (MSCs) and their derived exosomes (Exos) therapies showing distinct advantages. However, these therapies face several limitations, including issues related to ensuring stability and effective distribution within the body. Hydrogels, acting as an ideal carrier, can enhance the therapeutic effects and application range of MSCs and Exos derived from MSCs (MSC-Exos). Therefore, this review comprehensively summarizes the application progress of MSCs and MSC-Exos combined with hydrogels in age-related MSK disease research. It aims to provide a detailed perspective, showcasing the functional enhancement of MSCs and MSC-Exos when incorporated into hydrogels. Additionally, this review explores their potential and challenges in treating age-related MSK diseases, offering references for future research directions and potential innovative strategies.

01 Feb 2025·BRAIN RESEARCH BULLETIN

Therapeutic potential of mesenchymal stem cell-derived extracellular vesicles in ischemic stroke: A meta-analysis of preclinical studies

Article

Author: Guo, Yibing ; Huang, Xiangqian ; Fang, Kun ; Zhou, Da ; Meng, Ran ; Jia, Lina ; Zhang, Xiaoming ; Lan, Duo ; Ji, Xunming ; Wang, Mengqi

BACKGROUND:

Ischemic stroke (IS) remains a significant global health burden, necessitating the development of novel therapeutic strategies. This study aims to systematically evaluate the therapeutic effects of mesenchymal stem cell-derived exosomes (MSC-Exos) on IS outcomes in rodent models.

METHODS:

A comprehensive literature search was conducted across multiple databases to identify studies investigating the effects of MSC-Exos on rodent models of IS. Following rigorous inclusion and exclusion criteria, 73 high-quality studies were selected for meta-analysis. Primary outcomes included reductions in infarct volume/ratio and improvements in functional recovery scores. Data extraction and analysis were performed using RevMan 5.3 software.

RESULTS:

Pooled data indicated that MSC-Exos administration significantly reduced infarct size and improved functional recovery scores in rodent models of IS. Treatment within 24 hours and beyond 24 hours of stroke induction both demonstrated substantial reductions in infarct volume/ratio compared to controls. Furthermore, MSC-Exos-treated groups exhibited marked improvements in functional recovery, as assessed by various neurobehavioral tests. The meta-analysis showed no significant publication bias, and heterogeneity levels were acceptable.

CONCLUSIONS:

MSC-Exos reveal significant therapeutic potential for IS, with evidence supporting their efficacy in reducing infarct size and enhancing functional recovery in preclinical rodent models. These findings pave the way for further research and potential clinical translation.

01 Dec 2024·EXPERIMENTAL CELL RESEARCH

Exosomes derived from diabetic microenvironment-preconditioned mesenchymal stem cells ameliorate nonalcoholic fatty liver disease and inhibit pyroptosis of hepatocytes

Article

Author: Hu, Ruofan ; Zhang, HaiXia ; Wang, Anning ; Mu, Yiming ; Zhao, Jian ; Lyu, Zhaohui ; Li, Bing ; Zhang, Yue ; Su, Wanlu ; Cheng, Yu ; Ren, Rui

AIM:

Pyroptosis, a type of programmed cell death, is a key mechanism underlying non-alcoholic fatty liver disease (NAFLD). Mesenchymal stem cell (MSC)-derived exosomes (MSC-Exos) have the potential to ameliorate NAFLD, an effect that is enhanced by curcumin preconditioning. We previously reported that diabetic microenvironment preconditioning enhances the secretion capacity and anti-inflammatory activity of MSCs. Therefore, we hypothesized that MSC-Exos would inhibit hepatocyte pyroptosis and thereby ameliorate NAFLD, and that diabetic microenvironment preconditioning would enhance these effects.

METHODS:

MSCs were preconditioned in a diabetic microenvironment (pMSCs). MSC-Exos and pMSC-Exos collected from MSCs or pMSCs were applied to methionine- and choline-deficient (MCD)-induced NAFLD mice and in vitro models involving induction with lipopolysaccharide or palmitic acid to mimic hepatic steatosis and injury. MCC950 treatment was used as a positive control. We analyzed the characteristics of NAFLD and pyroptosis markers. Protein profiles of MSC-Exos and pMSC-Exos were evaluated by label-free quantitative proteomics.

RESULTS:

In vivo, MSC-Exos partially attenuated inflammation and fibrosis, but not lipid deposition and NAFLD progression in the livers of NAFLD mice. pMSC-Exos significantly improved lipid metabolism, hepatic steatosis, inflammation, and fibrosis but also retarded the progression of NAFLD. Pyroptosis was upregulated in the liver of NAFLD mice. MSC-Exos and pMSC-Exos inhibited pyroptosis, and the effect of the latter was greater than that of the former. In vitro, MSC-Exos and pMSC-Exos ameliorated hepatocyte steatosis, lipid metabolism disorder, and inflammation, and pMSC-Exos exerted a greater inhibitory effect on hepatocyte pyroptosis than MSC-Exos did, which were remitted after inhibition of peroxiredoxin-1 (PRDX-1).

CONCLUSION:

MSC-Exos ameliorated NAFLD and inhibited hepatocyte pyroptosis by downregulating the NLRP3/Caspase-1/GSDMD pathway, effects enhanced by pMSC-Exos, partly due to PRDX-1 upregulation.

100 Deals associated with Allogenic Adipose MSC-Exos(Cellular Biomedicine)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Respiratory Distress Syndrome, Acute	Phase 2	CN	AbelZeta Pharma, Inc.	30 Nov 2020
Alzheimer Disease	Phase 2	CN	AbelZeta Pharma, Inc.	01 Jul 2020
Respiratory Distress Syndrome, Adult	Phase 1	CN	Shanghai Cellular Biopharmaceutical Group Ltd.	16 Aug 2020
Respiratory Distress Syndrome, Adult	Phase 1	CN	Ruijin Hospital, Shanghai Jiaotong University School of Medicine	16 Aug 2020
COVID-19	Phase 1	CN	AbelZeta Pharma, Inc.	15 Feb 2020
COVID-19	Phase 1	CN	Ruijin Hospital, Shanghai Jiaotong University School of Medicine	15 Feb 2020

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04313647 (CTgov)	Phase 1	-	24	1X level of MSCs-Exo (1X Level)	borpxahsrj(xdkcikdidm) = ajpvymginv hejugisbmi (wighegnlds, sgaifofbry - vsjhxynodi) View more	-	04 Aug 2021
				2X level of MSCs-Exo (2X Level)	borpxahsrj(xdkcikdidm) = ujkdjkdzuz hejugisbmi (wighegnlds, rdnnjszrgd - ywachgkgds) View more